EPISODE · Jun 1, 2026 · 12 MIN
JCO at ASCO 2026: Pemigatinib Phase 3 FIGHT-302 Trial in Cholangiocarcinoma
from Journal of Clinical Oncology (JCO) Podcast
JCO Podcast host Dr. Davide Soldato and JCO Associate Editor Dr. Dr. Eileen M. O'Reilly discuss the ASCO 2026 Simultaneous Publication paper "Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial." LINK TO FULL TRANSCRIPT
Embed this episode
NOW PLAYING
JCO at ASCO 2026: Pemigatinib Phase 3 FIGHT-302 Trial in Cholangiocarcinoma
0:00
12:05
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Journal of Clinical Oncology (JCO) Podcast?
This episode is 12 minutes long.
When was this Journal of Clinical Oncology (JCO) Podcast episode published?
This episode was published on June 1, 2026.
Can I download this Journal of Clinical Oncology (JCO) Podcast episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!